1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
SCI Pharmtech Corp.

SCI Pharmtech Corp.

TTWSE:4119
52.90
TWD
-0.50
(-0.94%)
0.51EPS
88.02P/E
5.35BMarket Cap
Nov 06Next Earn
SCI Pharmtech Corp.
TWSE:4119
(Taiwan Stock Exchange)

Recent

price

52.90

P/E

ratio

88.02

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
12.73
13.23
16.46
13.67
15.75
18.27
17.87
11.95
17.8
21.61
24.67
7.93
8.38
11.02
12.75
11.24
10.67
Revenue per Share
2.19
1.15
2.54
1.69
2.8
3.77
3.92
1.75
4.1
5.24
3.3
0.51
2.88
2.7
4.47
0.9
0.51
Basic EPS, GAAP
0.37
1.3
2.7
-5.65
-1.02
4.5
3.56
1.23
2.92
5.39
6.92
-4.54
-8.12
-7.44
-0.72
-3.26
-1.48
Free Cash Flow per Basic Share
1.35
1.5
1.01
1.4
1.25
2.31
2.86
3.06
1.57
3.06
4.23
0.36
- -
0.22
1.25
1.5
- -
Dividend per Share
14.47
14.16
15.76
21.86
23.31
26.43
28.17
26.88
29.45
31.88
30.48
30.47
33.3
42.67
45.83
45.14
44.44
Book Value per Share
14.35
14.16
15.76
21.86
23.31
26.43
28.17
26.87
29.02
31.44
30.1
29.91
32.8
42.29
45.51
44.89
44.22
Tangible Book Value per Share
78
78
77
95
95
99
106
109
109
109
109
109
107
109
120
120
118
Basic Weighted Avg Shares
995
1,038
1,263
1,293
1,492
1,811
1,903
1,301
1,940
2,356
2,689
864
900
1,204
1,524
1,344
1,261
Sales/Revenue/Turnover
21.38
17.93
20
15.92
19.8
24.29
27.14
18.03
26.64
29.59
39.06
8.52
13.22
13.31
13.01
11.55
8.25
Operating Margin (%)
105
106
112
123
135
130
132
127
132
137
133
64
91
145
234
253
256
Depreciation Expense
171
90
195
160
265
374
417
191
447
571
360
56
309
295
535
107
60
Net Income, GAAP
15.09
15.37
18.38
17.46
20.97
17.18
17.55
18.66
17.91
19.69
20.89
14.98
20.38
19.07
17.34
- -
20.98
Effective Tax Rate (%)
17.22
8.67
15.44
12.37
17.75
20.65
21.91
14.68
23.05
24.24
13.39
6.44
34.32
24.48
35.09
7.99
4.77
Profit Margin (%)
171
190
247
996
933
863
1,168
996
1,150
1,352
797
649
272
1,383
646
54
214
Working Capital
- -
- -
- -
563
577
- -
- -
- -
- -
1
1
1
433
846
584
303
617
LT Debt
1,131
1,117
1,248
2,068
2,226
2,762
3,071
2,930
3,210
3,475
3,322
3,321
3,629
5,100
5,477
5,394
5,310
Total Equity
15.09
5.98
15.66
8.34
8.27
12.72
14.29
6.27
13.55
16.29
23.68
1.85
2.5
2.5
2.58
- -
1.29
Return on Invested Capital (%)
14.55
6.88
15.04
8.04
9.68
13.57
14.35
6.36
14.57
17.08
10.59
1.68
8.26
5.81
8.55
- -
1.05
Return on Capital (%)
15.79
8.01
16.49
9.65
12.33
14.99
14.3
6.37
14.57
17.09
10.6
1.68
8.89
6.75
10.11
1.98
1.12
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
684
744
444
LT Borrowings
258
300
575
LT Finance Leases
44
43
42
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
120
120
120
Market Capitalization
5,820
6,083
5,354

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,090
1,105
1,063
Cash, Cash Equivalents & STI
75
53
84
Accounts Receivable, Net
248
332
193
Inventories
728
680
730
Total Current Liabilities
1,036
1,053
849
Payables & Accruals
- -
- -
- -
ST Debt
684
744
444
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.56%
11.13%
-1.51%
Free Cash Flow
33.74%
33.43%
352.72%
Net Income, GAAP
44.91%
73.36%
-79.92%
Sales/Revenue/Turnover
4.3%
-3.04%
-11.81%
Total Cash Common Dividend
- -
- -
20%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
310
393
419
402
1,524
2025
360
372
256
355
1,344
2026
376
273
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.37
0.52
3.19
0.39
4.47
2025
0.27
0.19
0.12
0.33
0.9
2026
0.17
-0.11
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.25
2025
- -
- -
- -
- -
1.5
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
SCI Pharmtech, Inc. (4119.TW) manufactures and markets advanced drug delivery systems and pharmaceutical excipients for the global healthcare industry. The company produces a range of lipid-based products including Captex, Miglyol, and Labrafil for oral, topical, and parenteral applications; self-emulsifying drug delivery systems (SEDDS) such as Gelucire and Labrasol for bioavailability enhancement; and specialty excipients like Maisine CC and Transcutol for solubility and permeation support. SCI Pharmtech operates primarily in the pharmaceutical ingredients and contract development and manufacturing organization (CDMO) segments, serving pharmaceutical companies, nutraceutical firms, and research institutions with tailored formulation solutions; its target markets include North America, Europe, Asia-Pacific, and emerging regions. Founded in 1999 and headquartered in Taoyuan City, Taiwan, the company maintains manufacturing facilities in Taiwan and sales offices across key international markets to support its global customer base. In recent developments, SCI Pharmtech expanded its CDMO capabilities through a strategic partnership with a leading European pharmaceutical firm in early 2025 to co-develop lipid-based formulations for poorly soluble APIs, enhancing its position in complex generics. The company also completed a NT$500 million funding round in mid-2024 led by existing investors to scale production of high-potency SEDDS technologies amid rising demand for oral biologics delivery. Additionally, SCI Pharmtech launched two new product lines in late 2024—Capmul series for lymphatic drug targeting and a green chemistry-compliant Labrafac variant—while pursuing regulatory approvals in the U.S. and EU markets. No major acquisitions, name changes, or reorganizations have been reported in the last two years, with the focus remaining on organic growth in lipid excipient innovation and sustainable manufacturing practices.